NL-OMON20279
Recruiting
未知
Study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett's Esophagus - part 2
Aqua Medical, Inc.0 sites19 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Aqua Medical, Inc.
- Enrollment
- 19
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Flat Barrett's esophagus (BE) with an indication for ablation therapy ( either flat confirmed LGD, flat HGD, or residual flat BE after endoscopic resection of early, non\-flat BE neoplasia)
Exclusion Criteria
- •Presence of visible lesions, history of advanced BE neoplasia (either sm2\+, LVI\+ or G3\+).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett*s Esophagus - part 2Esophageal CarcinomaIntestinal Metaplasia1001799010017991NL-OMON55125Academisch Medisch Centrum28
Not yet recruiting
Not Applicable
Soft capsules with ozonated sunflower oil versus oral OLEOZON® in patients with GiardiosisGiardiosisRPCEC00000440ational Centre for Scientific Research (CNIC)200
Not yet recruiting
Phase 3
Abexol (suspension) versus Abexol (tablets) in patients with gastrointestinal symptomsGastrointestinal symptomsSigns and Symptoms, DigestiveDigestive System DiseasesRPCEC00000372ational Centre for Scientific Research100
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
Completed
Not Applicable
study on low back paiCTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd